Author (Year) |
Country |
Study Design |
N of acne patients |
Age (years) |
Oral
isotretinoin dosage |
Treatment duration (months) |
Control |
Parameters assessed |
Laker (1987)24
|
U.K. |
Cohort |
13 (M:F = 10:3) |
13-32* |
1.0 mg/kg/day |
4 |
no |
glucose, insulin |
Koistinen (2001)25
|
Finland |
Cohort |
11 (M:F=11:0) |
24 (2)^ |
∼0.5 mg/kg/day |
4–6 |
no |
glucose,HbA1c%,
insulin |
Stoll (2004)26
|
Switzerland |
Cohort |
15 (M:F=15:0) |
28.3 (1.7)^ |
1.0 mg/kg/day |
5 days1
|
no |
glucose, insulin |
Koistinen (2006)27
|
Finland |
Cohort |
11 (M:F=11:0) |
24 (2)^ |
∼0.5 mg/kg/day |
5 (6-10)* |
no |
adiponectin |
Heliövaara (2007)28
|
Finland |
Cohort |
23
(M:F=12:11) |
24.9 (0.9)^ |
N/A |
3 |
no |
adiponectin, glucose,
insulin |
Ertugrul (2010)7
|
Turkey |
Cohort |
48 (M:F=13:35) |
22 (18-38)** |
0.5–0.75 mg ⁄kg/day, adjusted to 0.88 mg ⁄kg ⁄day 1
month after |
≥4 |
no |
glucose, insulin, HOMA-IR |
Cetinözman (2013)29
|
Turkey |
Case-control |
26
(M:F=0:26) |
24.7 (3.9)^ |
20mg/day increased to max.50mg/day |
7.5
(6-10)* |
yes |
glucose/insulin, HOMA-IR |
Karadag (2015)30
|
Turkey |
Case-control |
33
(M:F=15:18) |
19.8 (4.1)^ |
N/A |
3 |
yes |
adiponectin, glucose,
insulin |
Cemil (2016)31
|
Turkey |
Cohort |
32 (M:F=20:12) |
18.9 (2.57)^ |
0.5-0.6mg/kg/day adjusted to 0.6-0.75 mg/kg/day after
1 month |
3 |
no |
adiponectin |
Saklamaz (2016)19
|
Turkey |
Cohort |
21 (M:F=6:15) |
23.0 (4.1)^ |
0.5-0.8 mg/kg/day |
4 |
no |
glucose, insulin,
HOMA-IR |
Aydin (2017)20
|
Turkey |
Case-control |
18 (M:F=0:18) |
23.4 (3.4)^ |
20mg/day increased to max.50mg/day |
6 |
yes |
adiponectin, glucose, insulin, HOMA-IR |
Soyuduru (2019)8
|
Turkey |
Case-control |
29
(M:F=15:14) |
20.5 (1.9)^ |
0.5 mg/kg/day |
5 |
yes |
adiponectin,
HOMA-IR |
Acmaz (2019)21
|
Turkey |
Cohort |
40 (M:F=0:40) |
18-40* |
20 mg/day increased to max. 40mg/day |
6 |
no |
insulin |
Koçyiğit (2020)22
|
Turkey |
Case-control |
30
(M:F=0:30) |
23.2 (3.7)^ |
120-150 mg/kg/day |
3 |
yes |
glucose,
insulin, HOMA-IR |
Aktar (2021)23
|
Turkey |
Case-control |
30 (M:F=0:30) |
22.1 (3.4)^ |
0.5mg/kg/day |
3 |
yes |
glucose,
insulin |
Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for
Insulin Resistance; M, males; N/A, not available. |
Abbreviations: F,
females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance;
M, males; N/A, not available. |
Abbreviations: F, females; HOMA-IR,
Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not
available. |
Abbreviations: F, females; HOMA-IR, Homeostatic Model
Assessment for Insulin Resistance; M, males; N/A, not available. |
Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for
Insulin Resistance; M, males; N/A, not available. |
Abbreviations: F,
females; HOMA-IR, Homeostatic Model Assessment for Insulin Resistance;
M, males; N/A, not available. |
Abbreviations: F, females; HOMA-IR,
Homeostatic Model Assessment for Insulin Resistance; M, males; N/A, not
available. |
Abbreviations: F, females; HOMA-IR, Homeostatic Model
Assessment for Insulin Resistance; M, males; N/A, not available. |
Abbreviations: F, females; HOMA-IR, Homeostatic Model Assessment for
Insulin Resistance; M, males; N/A, not available. |
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|
*Range
^Mean (SD)
**Median (IQR)
1Previous treatment with isotretinoin on average 5
years earlier (3-10)
|